Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 08:00 ET | Source: LifeVantage Corporation

LifeVantage Announces Expansion of its European Footprint with Market Opening in Portugal

SALT LAKE CITY, April 02, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the...
April 02, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
April 02, 2026 07:54 ET | Source: WOLFSON BRANDS (UK) LIMITED

Strongest Phentermine Alternatives For Weight Loss 2026: Over The Counter - Lunched by Wolfson brands How To Take Phentermine 37.5 Diet Pills for Best Results?

New York City, April 02, 2026 (GLOBE NEWSWIRE) -- Wolfson brands launch the strongest Phentermine Alternatives in 2026. To unlock the full potential of Phentermine in your weight loss journey,...
April 02, 2026 07:43 ET | Source: Yukon Metals Corp.

Yukon Metals Intersects 11.7 g/t Gold Within Extensive Vein System in First Drill Program and Expands Land Package at Star River Property

YUKON METALS INTERSECTS 11.7 G/T GOLD WITHIN EXTENSIVE VEIN SYSTEM IN FIRST DRILL PROGRAM AND EXPANDS LAND PACKAGE AT STAR RIVER PROPERTY
April 02, 2026 07:30 ET | Source: Annovis Bio Inc.

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
April 02, 2026 07:30 ET | Source: Context Therapeutics Inc.

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02,...
April 02, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
April 02, 2026 07:01 ET | Source: Adagene Inc.

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide...
April 02, 2026 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
April 02, 2026 07:00 ET | Source: Manufacturing by Informa

Speakers Announced for The Battery Show Europe 2026

Manufacturing by Informa’s European event will feature the European Commission, Mercedes-Benz, Schneider Electric, and more.